Cargando…

Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum

PURPOSE: The purpose of this study was to evaluate the anti-tumor activity and safety of anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with gemcitabine plus platinum (GP) as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chen, Zhang, Xuanye, Zhou, Yixin, Fu, Sha, Lin, Zuan, Hong, Shaodong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585779/
https://www.ncbi.nlm.nih.gov/pubmed/33116890
http://dx.doi.org/10.2147/CMAR.S275947
_version_ 1783599860786659328
author Chen, Chen
Zhang, Xuanye
Zhou, Yixin
Fu, Sha
Lin, Zuan
Hong, Shaodong
Zhang, Li
author_facet Chen, Chen
Zhang, Xuanye
Zhou, Yixin
Fu, Sha
Lin, Zuan
Hong, Shaodong
Zhang, Li
author_sort Chen, Chen
collection PubMed
description PURPOSE: The purpose of this study was to evaluate the anti-tumor activity and safety of anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with gemcitabine plus platinum (GP) as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). PATIENTS AND METHODS: This retrospective study analyzed RM-NPC patients at Sun Yat-sen University Cancer Center who received anti-EGFR antibody plus GP as a first-line treatment between July 2007 and November 2018. Survival analyses were performed using the Kaplan–Meier method with Log rank test. Cox proportional hazards model was used for the multivariate analysis. RESULTS: A total of 84 patients were enrolled. The median progression-free survival (PFS) was 10.3 months (95% CI, 6.9–13.6 months), and the median overall survival (OS) was 42.8 months (95% CI, 24.6–60.9 months). The objective response rate and disease control rate were 67.9% and 92.9%, respectively. The multivariate analysis identified a higher baseline EBV DNA level as a risk factor for both PFS (P=0.025) and OS (P=0.013). Additionally, age≥44 years (P =0.003), non-cisplatin (P= 0.009), and poor KPS (≤80) (P =0.034) were other risk factors for OS. The most common adverse events were leukopenia (n=73, 86.9%). The most common grade 3–4 AEs were leukopenia (n=30, 35.7%) and thrombocytopenia (n=22, 26.2%). CONCLUSION: Anti-EGFR monoclonal antibody plus GP achieved promising antitumor activity with a tolerable toxicity profile in RM-NPC as a first-line treatment. Randomized clinical trials are warranted to compare the efficacy of GP with or without anti-EGFR antibody in these patients.
format Online
Article
Text
id pubmed-7585779
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75857792020-10-27 Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum Chen, Chen Zhang, Xuanye Zhou, Yixin Fu, Sha Lin, Zuan Hong, Shaodong Zhang, Li Cancer Manag Res Original Research PURPOSE: The purpose of this study was to evaluate the anti-tumor activity and safety of anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with gemcitabine plus platinum (GP) as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). PATIENTS AND METHODS: This retrospective study analyzed RM-NPC patients at Sun Yat-sen University Cancer Center who received anti-EGFR antibody plus GP as a first-line treatment between July 2007 and November 2018. Survival analyses were performed using the Kaplan–Meier method with Log rank test. Cox proportional hazards model was used for the multivariate analysis. RESULTS: A total of 84 patients were enrolled. The median progression-free survival (PFS) was 10.3 months (95% CI, 6.9–13.6 months), and the median overall survival (OS) was 42.8 months (95% CI, 24.6–60.9 months). The objective response rate and disease control rate were 67.9% and 92.9%, respectively. The multivariate analysis identified a higher baseline EBV DNA level as a risk factor for both PFS (P=0.025) and OS (P=0.013). Additionally, age≥44 years (P =0.003), non-cisplatin (P= 0.009), and poor KPS (≤80) (P =0.034) were other risk factors for OS. The most common adverse events were leukopenia (n=73, 86.9%). The most common grade 3–4 AEs were leukopenia (n=30, 35.7%) and thrombocytopenia (n=22, 26.2%). CONCLUSION: Anti-EGFR monoclonal antibody plus GP achieved promising antitumor activity with a tolerable toxicity profile in RM-NPC as a first-line treatment. Randomized clinical trials are warranted to compare the efficacy of GP with or without anti-EGFR antibody in these patients. Dove 2020-10-20 /pmc/articles/PMC7585779/ /pubmed/33116890 http://dx.doi.org/10.2147/CMAR.S275947 Text en © 2020 Chen et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Chen, Chen
Zhang, Xuanye
Zhou, Yixin
Fu, Sha
Lin, Zuan
Hong, Shaodong
Zhang, Li
Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
title Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
title_full Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
title_fullStr Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
title_full_unstemmed Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
title_short Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
title_sort treatment of recurrent or metastatic nasopharyngeal carcinoma by targeting the epidermal growth factor receptor combined with gemcitabine plus platinum
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585779/
https://www.ncbi.nlm.nih.gov/pubmed/33116890
http://dx.doi.org/10.2147/CMAR.S275947
work_keys_str_mv AT chenchen treatmentofrecurrentormetastaticnasopharyngealcarcinomabytargetingtheepidermalgrowthfactorreceptorcombinedwithgemcitabineplusplatinum
AT zhangxuanye treatmentofrecurrentormetastaticnasopharyngealcarcinomabytargetingtheepidermalgrowthfactorreceptorcombinedwithgemcitabineplusplatinum
AT zhouyixin treatmentofrecurrentormetastaticnasopharyngealcarcinomabytargetingtheepidermalgrowthfactorreceptorcombinedwithgemcitabineplusplatinum
AT fusha treatmentofrecurrentormetastaticnasopharyngealcarcinomabytargetingtheepidermalgrowthfactorreceptorcombinedwithgemcitabineplusplatinum
AT linzuan treatmentofrecurrentormetastaticnasopharyngealcarcinomabytargetingtheepidermalgrowthfactorreceptorcombinedwithgemcitabineplusplatinum
AT hongshaodong treatmentofrecurrentormetastaticnasopharyngealcarcinomabytargetingtheepidermalgrowthfactorreceptorcombinedwithgemcitabineplusplatinum
AT zhangli treatmentofrecurrentormetastaticnasopharyngealcarcinomabytargetingtheepidermalgrowthfactorreceptorcombinedwithgemcitabineplusplatinum